The Pharma Data

NOVEMBER 29, 2020

C-Founder of Ascentage Pharma and Chairman of its Scientific Advisory Board, and Warner-Lambert/Parke-Davis Professor in Medicine, Professor of Internal Medicine, Pharmacology and Medicinal Chemistry, Director of Michigan Center for Therapeutic Innovation, University of Michigan , is a leading researcher in the field. Shaomeng Wang, Ph.D.,

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

NOVEMBER 18, 2020

Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. .” Presentation number: 397P / Poster: ID 680. Presenter: Ching-Liang Ho MD, et.al. Session Title: E-poster Display session – Thoracic tumours, metastatic.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

OCTOBER 18, 2020

Dr. Berk completed his internship, residency, and fellowship in internal medicine, hematology, and medical oncology at the Weill Cornell Medical College and New York Presbyterian Hospital, where he also served as a faculty member. Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

MARCH 1, 2022

” The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018. Source link: [link].

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

The Pharma Data

JANUARY 17, 2021

On December 17, 2020, Aurinia inked a collaboration and license deal with Japan’s Otsuka Pharmaceutical Co. Myelosuppression happens when radiation damages internal organs, including bone marrow. By inhibiting calcineurin, the drug blocks IL-2 expression and T-cell mediated immune responses.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

OCTOBER 14, 2020

International Dial-in Number: (210) 874-7715. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. Conference Call Information : Date : Thursday, November 5, 2020. Time : 4:30 p.m. Domestic Dial-in Number : (866) 913-8546.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

Drug Target Review

NOVEMBER 22, 2023

We will present some of the data at the end of the study at an international conference next year. Initially we would like to investigate combination strategies of our autotaxin inhibitor, IOA-289, with TGF-β molecules that have already been in the clinic.

Licensing 52

Licensing Licensing Small Molecule Therapies 52

The Pharma Data

JANUARY 13, 2021

The patent application is titled “Anti-CD154 Antibodies and Uses Thereof” and published under International Publication No. International Immunol. (11):1583 The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. WO 2021/001458 A1. Structure.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

DECEMBER 15, 2020

Small Molecule Inhibitors. NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel. Oral, Small Molecules. KAN-101 is in a randomized, double-blind, placebo-controlled Phase I study, Assessment of KAN-101 in Celiac Disease.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

MARCH 4, 2021

The live event will be available on the investor page of the Ovid Therapeutics website at investors.ovidrx.com or by dialing (866) 830-1640 (domestic) or (210) 874-7820 (international) and referencing conference ID number 6343028. Ovid’s most advanced pipeline programs include OV935 (soticlestat) in collaboration with Takeda and OV101 a ?-selective

Treatment 52

Treatment Clinical Trials Pharmaceutical Companies Trials 52

Agency IQ

JULY 26, 2024

For additional information on this process, sponsors should refer to International Council for Harmonisation (ICH) guidelines Q8, Q9 and Q10 on the development of quality risk management processes, and the steps to conducting the risk assessment. including well before and after product approval). Any CMC changes (e.g.,

Biosimilars 40

Biosimilars Science FDA Production 40

The Pharma Data

FEBRUARY 4, 2021

Net Revenues of $4.305 Billion and International Profit Sharing of $1.009 Billion; Global Venclexta Net Revenues Were $1.337 Billion. net revenues of $1.165 billion and international profit sharing of $259 million. Reflects profit sharing for Imbruvica international revenues. *. Percent on a Reported Basis, or 13.4

Production 52

Production Clinical Trials International Small Molecule 52

The Pharma Data

SEPTEMBER 15, 2020

The results demonstrated that Penta immune responses were robust and noninferior to licensed meningococcal vaccines (MenB and MenACWY) in individuals 10-25 years of age, regardless of prior MenACWY exposure. Internal Medicine. These results were presented in August at the Digital International Liver Congress 2020.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

AUGUST 3, 2021

The company announced donanemab received Breakthrough Therapy designation for treatment of Alzheimer’s disease and its intention to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. Loxo Oncology at Lilly and Kumquat Biosciences Inc.

Production 52

Production Marketing Research DNA 52

Agency IQ

NOVEMBER 3, 2023

One non-profit organization, the International Society Association for Probiotics and Prebiotics (ISAPP) , which is dedicated to promoting research in this area, has published consensus statements that have helped to define some of these terms and their associated substances.

Therapies 40

Therapies Science FDA Production 40

The Pharma Data

APRIL 27, 2021

up 60%) driven by increase disease and product awareness as well as adoption of new ISTH (International Society on Thrombosis and Haemostasis) TTP guidelines. On January 12, 2021 Sanofi entered into a global licensing agreement with Biond Biologics for BND-22, a novel immune checkpoint inhibitor targeting the ILT2 receptor.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

DECEMBER 12, 2020

AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. Click here for available international numbers. Morgan Stanley and Goldman Sachs International are joint corporate brokers.

Regulations 75

Regulations International Disease Small Molecule 75

The Pharma Data

MAY 6, 2021

The IOC and International Paralympics Committee (IPC) have made it clear that vaccination is not mandatory in order for athletes to participate in the Olympic and Paralympic Games, and that any vaccination program must be conducted in full respect of national vaccination priorities.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 22, 2020

In parallel, Cytokinetics plans to conduct commercial readiness assessments and to evaluate potential partnering opportunities, including co-promotion options in North America as well as licensing in other territories. Cytokinetics will have no trailing royalty payment obligations to Amgen for either omecamtiv mecarbil or AMG 594.

Clinical Trials 52

Clinical Trials Licensing Licensing Trials 52

The Pharma Data

DECEMBER 27, 2020

BRUKINSA (zanubrutinib) is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), discovered by BeiGene scientists, that is currently being evaluated globally in a broad pivotal clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. About BRUKINSA ® (zanubrutinib).

Production 52

Production Therapies Treatment Drugs 52

The Pharma Data

OCTOBER 26, 2020

billion related to certain license and collaboration agreements, and certain other items. The results were presented at the Virtual European Respiratory Society (ERS) International Congress 2020. Non-GAAP EPS of $1.74 Year-to-date results can be found in the attached tables. COVID-19 Research Highlights. Canada and Europe.

Vaccine 40

Vaccine Trials Treatment Therapies 40

The Pharma Data

NOVEMBER 8, 2020

We have done this by both internal talent development as well as by external hires. 10% of its Net Sales in R&D and also invests significantly in business development and in-licensing. Tirbanibulin is a topical drug for the treatment of actinic keratosis in adult patients developed by Athenex and licensed by Almirall.

Licensing 52

Licensing Licensing Production Marketing 52

The Pharma Data

AUGUST 3, 2021

HLE BiTE ® molecules AMG 199 and AMG 910, targeting mucin 17 (MUC17) and claudin 18.2 AMG 176, a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1), continues to enroll patients with hematologic malignancies. CLDN18.2), respectively, continue to enroll patients with gastric and gastroesophageal junction cancer.

Biosimilars 52

Biosimilars Production Treatment FDA 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 4, 2020

and Canada) or (484) 365-2865 (International) five minutes prior to the start time. License and research and development revenue. ET to provide an update on the Company and discuss third quarter financial results. To access the conference call, please dial (855) 354-1855 (U.S. 2019.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Treatment 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. the United States. the United States.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 9, 2020

Today’s decision is a further illustration of how collaboration and solidarity can help address a global health crisis as an international community,” said Ugur Sahin, M.D., Our aim is to develop a safe and effective vaccine to contribute to bringing this pandemic to an end in Europe and across the world. CEO and Co-founder of BioNTech.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

Drug Target Review

FEBRUARY 11, 2025

Drugs that were developed and commercialised 30+ years ago were relatively simple small molecules. Todays small molecules are far larger, more complex, and chase highly specific (and difficult to hit) targets, thereby increasing the chances of undesired side effects. This failure is getting more pronounced by the day.

Drug Development 59

Drug Development Bioinformatics Drugs Small Molecule 59

The Pharma Data

JUNE 24, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Government 52

Government Vaccine Clinical Trials Licensing 52